Ovid Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ovid Therapeutics Inc. on October 7, 2021, reporting events occurring on October 6, 2021. The Company is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "OVID". The Company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Dr. Kevin Fitzgerald, Ph.D., as a director of the Company, effective immediately on October 6, 2021. Dr. Fitzgerald was appointed as a Class II director, with a term expiring at the 2022 annual meeting of stockholders. No committee assignments were determined at the time of filing.
Compensation and Governance Details
- Cash Compensation: Dr. Fitzgerald is entitled to annual cash compensation of $40,000, prorated based on actual days served in the fiscal year, plus reimbursement of travel expenses.
- Initial Equity Grant: On October 6, 2021, Dr. Fitzgerald was granted an option to purchase 30,000 shares of common stock at an exercise price of $3.44 per share. These shares vest monthly over a three-year period, contingent on continued service.
- Future Equity Grants: Dr. Fitzgerald will receive an annual option grant for 15,000 shares following each annual meeting of stockholders, subject to continued service. These annual grants vest in full twelve months after the grant date.
- Indemnification: Dr. Fitzgerald has entered into the Company's standard director and officer indemnity agreement.
Risks and Contingencies
The filing states there are no arrangements or understandings between Dr. Fitzgerald and any other person regarding his election. He has no family relationships with other directors or officers and no direct or indirect material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and exercise price ($3.44) of the initial 30,000 share option grant.
- Confirm future committee assignments for Dr. Fitzgerald once determined by the Board.
- Review the Company's Non-Employee Director Compensation Policy for any updates affecting future annual grants.
- Monitor the Company's 2022 annual meeting for the expiration of Dr. Fitzgerald's initial director term.